Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children

NCT07095894 is registered in ClinicalTrials.gov with Jaeb Center for Health Research as lead sponsor.

NCT NCT07095894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07095894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children
Lead sponsor
Jaeb Center for Health Research
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2026
Completion date
June 1, 2029
Enrollment
348 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

myopia